Multi-client Study: Opportunities Assessment for the Hepatitis C Therapeutics Market in Malaysia

Frost & Sullivan, May 2010, Pages: 62

This research service aims to provide an update on the epidemiology of Hepatitis C, including the prevalence and incidence, Market Engineering measurements, and government initiatives. It also covers patient source, load, and forecasts, while also outlining the key treaters involved. Current diagnostic methods are presented, followed by treatment regimens, their cost, and upcoming product launches. Clinical trials highlighting research into new treatments are also provided, along with an analysis of the pipeline. Additionally, there is a competitive analysis which includes the market structure, major participants, and future trends. This service covers the Hepatitis C therapeutics market in Malaysia.

This Frost & Sullivan research service titled Multi-client Study: Opportunities Assessment for the Hepatitis C Therapeutics Market in Malaysia provides an overview of the Hepatitis C market, government initiatives, patient load and classification, patient forecasts, treatment regimens, product launches, and challenges faced by physicians. In this research, Frost & Sullivan's expert analyst provides a list of current and pipeline products for Hepatitis C therapeutics.

This analysis is available through our Pharmaceuticals & Biotechnology Growth Partnership Service program. With continuous access to intelligence and resources from all seven perspectives of the Complex Business Universe, the Growth Partnership Services program ensures that you and your Growth Team™ are able to maintain a 360 Degree Perspective of the market. This comprehensive, objective information allows your company to mitigate risk, identify new opportunities, and drive effective strategies for growth.

Market Overview

The Imminent Development and Launch of Improved Agents to Enhance Treatment Success Rates for Hepatitis C

Owing to Malaysia’s efforts to raise disease awareness, there has been a spurt in the number of Hepatitis C-diagnosed cases in the country, which, in turn, has expanded the patient pool for Hepatitis C virus (HCV) treatment. The high success rates of the current standard treatment of Pegylated Interferon and Ribavirin on Genotype 2 and 3 patients have encouraged more patients to seek this line of treatment. However, the positive patient response to the combination therapy of Pegylated Interferon and Ribavirin has been diluted by the long duration and known side effects of the treatment. “Treatment duration vary from 24 to 48 weeks, requiring weekly visits to physicians, while the side effects include bone marrow depression, flu-like symptoms, neuropsychiatric disorders, and autoimmune syndromes,” says the analyst of this research. “These factors lower patients’ compliance and sometimes result in treatment discontinuation.”

Companies that offer disease education and explore new treatments that improve efficacy and decrease side effects, which are likely to increase compliance, are very likely to succeed in the market. Refined versions of current HCV drugs, oral formulations of small molecule inhibitors, and a new drug class known as protease inhibitors are in the pipeline and represent the future of HCV treatment. Creating incentives for patients to stay the course of the current HCV treatment will increase the rates of patient compliance with the new, improved treatments. “In order to increase their HCV market share with newer drugs, companies must make sure that patients are aware of their disease status and are willing to try new treatments,” notes the analyst. “Creating marketing campaigns that highlight better efficacy, as well as partnerships with governments to lower costs and increase distribution, will enhance their market presence.”

Frost & Sullivan Growth Partnership Services

Frost & Sullivan's Growth Partnership Services empower companies to accelerate their growth by achieving top-line improvements and bottom-line results. This is accomplished by helping our clients execute successful growth strategies and providing their Growth Teams™ with the skills, know-how, and tools to generate growth opportunities, evaluate these opportunities to create a growth pipeline, and implement a growth strategy to deliver measurable business results.

1 | EXECUTIVE SUMMARY

- - Overview
- - - 1. Executive Summary—Malaysia

- 2 | HEPATITIS C THERAPEUTICS MARKET

- - Market Overview
- - - 1. Introduction

- 3 | MALAYSIAN HEPATITIS C THERAPEUTICS MARKET

- - Market Overview
- - - 1. Introduction
- - - 2. Measurements
- - - 3. Government Initiatives

- Hepatitis C Patients
- - - 1. Patient Source and Quantification
- - - 2. Key Treaters and Patient Flow
- - - 3. Patient Forecasts—Diagnosed Patients
- - - 4. Patient Forecasts—Treated Patients

- Diagnosis and Treatment
- - - 1. Diagnostic Tests and Monitoring
- - - 2. Treatment Regimens
- - - 3. Cost of Treatment
- - - 4. Product Launches
- - - 5. Clinical Trials

- Competitive Analysis
- - - 1. Competitive Structure
- - - 2. Future Trends
- - - 3. Problems Faced by Physicians

- 4 | APPENDIX

- - Supporting References
- - - 1. Appendix—Malaysia

List of Figures

- Chapter 3
- Hepatitis C Therapeutics Market: Prevalence of Hepatitis C (Malaysia), 2006-2016
- Hepatitis C Therapeutics Market: Incidence of Hepatitis C (Malaysia), 2006-2016
- Hepatitis C Therapeutics Market: Patient Split Between Diagnosed Acute and Chronic HCV Patients (Malaysia), 2009
- Hepatitis C Therapeutics Market: Categorization of Patients Based on Genotype (Malaysia), 2009
- Hepatitis C Therapeutics Market: Patient Classification of Current HCV Patients Based on Interferon Usage (Malaysia), 2009
- Hepatitis C Therapeutics Market: Categorization of Patients Previously Treated with Interferons (Malaysia), 2009
- Hepatitis C Therapeutics Market: Diagnosed Hepatitis C Patients Forecasts (Malaysia), 2006-2016
- Hepatitis C Therapeutics Market: Market Drivers Ranked in Order of Impact (Malaysia), 2010-2016
- Hepatitis C Therapeutics Market: Market Restraints Ranked in Order of Impact (Malaysia), 2010-2016
- Hepatitis C Therapeutics Market: Treated Hepatitis C Patients Forecasts (Malaysia), 2006-2016
- Hepatitis C Therapeutics Market: Treated Acute and Chronic Hepatitis C Patients Forecasts (Malaysia), 2006-2016
- Hepatitis C Therapeutics Market: Circumstances that Prompt Physicians to Test Patients for HCV (Malaysia), 2009
- Hepatitis C Therapeutics Market: Key Diagnostic Tests Required Prior to Initiating Therapy for Infection with HCV (Malaysia), 2009
- Hepatitis C Therapeutics Market: Tests Used and Key Clinical Indicators that Confirm a Patient's Progression from Acute HCV to Chronic Disease (Malaysia), 2009
- Hepatitis C Therapeutics Market: Percent of Usage of Pegasys and Peg Intron (Malaysia), 2009
- Hepatitis C Therapeutics Market: Treatment Regimen for Acute HCV Patients (Malaysia), 2009
- Hepatitis C Therapeutics Market: Treatment Regimen for Genotype 1 Chronic HCV Patients (Malaysia), 2009
- Hepatitis C Therapeutics Market: Treatment Regimen for Genotype 2/3 Chronic HCV Patients (Malaysia), 2009
- Hepatitis C Therapeutics Market: Advantages and Drawbacks of Drugs Prescribed (Malaysia), 2009
- Hepatitis C Therapeutics Market: Average Monthly Cost of Treatment of Various Regimens (Malaysia), 2009
- Hepatitis C Therapeutics Market: List of Clinical Trials Conducted by Phase, Patient Age, Stage, Drug, and Sponsor (Malaysia), 2009
- Hepatitis C Therapeutics Market: List of Interferons in Development (World), 2009
- Hepatitis C Therapeutics Market: List of Small-molecule Anti-virals in Development (World), 2009
- Hepatitis C Therapeutics Market: List of Non-Interferons in Development (World), 2009
- Hepatitis C Therapeutics Market: Competitive Structure (Malaysia), 2009
- Hepatitis C Therapeutics Market: Treatment Forecasts (Malaysia), 2009-2016

- Chapter 4
- Hepatitis C Therapeutics Market: Total Population and Population Growth Rate (Malaysia), 2006-2016
- Hepatitis C Therapeutics Market: Assumptions Used in Estimating Patient Forecasts (Malaysia), 2009
- Hepatitis C Therapeutics Market: Assumptions Used in Estimating Treatment Forecasts (Malaysia), 2009

Product Samples

A sample for this product is available. Please Login/Register to download this sample.

Customers who bought this item also bought

• Antiviral Therapeutics - Technologies, Markets and Companies
• Biosimilars (2009 - 2014)
• Global Microbiology Testing Market: US, Europe, Japan - Emerging Opportunities and Business Expansion Strategies for Suppliers
• Global Nucleic Acid Testing Market - New Product Development Opportunities and Business Expansion Strategies For Instrument and Reagent Suppliers
• Biobetters in Key Markets - Opportunities for Biotechnology Companies to Sustain Innovation with Low Risk and High Value Offerings
• The Antivirals Outlook To 2007: Marketing Opportunities By Disease State, Patient Potential And Product Profile
• Stem Cell Research - Global Business Strategic Report
• 07 - 2012 Emerging Medical Technologies Spotlight: A Report of Investment & Partnering Opportunities
• RNAi - Technologies, Markets and Companies
• Polymerase Chain Reaction (PCR): Products/Tools - A Global Market Watch, 2009-2015